findmyKOL
Clinical trialNCT04864054RecruitingPhase 1/PHASE2Interventional

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

SponsorEureka Therapeutics Inc.Enrollment60Hepatocellular CarcinomaLiver Cancer, AdultLiver NeoplasmMetastatic Liver Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Taiwan
  • National Taiwan University Cancer Center

    Taipei, Taiwan

    Chiun Hsu, MD, PhD
    Recruiting
United States
  • City of Hope

    Duarte, California, United States

    Daneng Li, MD
    Recruiting
  • Kansas University Medical Center, Principal Investigator:

    Westwood, Kansas, United States

    Completed
  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, United States

    Completed
  • Montefiore Einstein Comprehensive Cancer Center

    The Bronx, New York, United States

    R. Alejandro Sica, MD
    Recruiting
  • Oregon Health and Sciences University

    Portland, Oregon, United States

    Adel Kardosh, MDRichard Maziarz, MD
    Recruiting
  • University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas, United States

    David Hsieh, MDFarrukh Awan, MD
    Recruiting
  • Fred Hutchinson Cancer Center, University of Washington

    Seattle, Washington, United States

    William Harris, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ECT204 T cells
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Mar 2022
Primary completion
31 Dec 2027
Completion
31 Dec 2027
Last update posted
9 Jun 2026
Registered enrollment
60
Registry id
NCT04864054
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.